alexa
Reach Us +1-947-333-4405
Potent Neutralizing Antibodies Against CMV Infection Of Both Fibroblast And Epithelial Cell Infection Induced Using A Multivalent EVLP Vaccine Candidate | 9832
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Vaccines & Vaccination

David E. Anderson
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
Background: A prophylactic vaccine to prevent congenital transmission of Cytomegalovirus (CMV) is the highest public health vaccine priority for which a vaccine is currently lacking. Several lines of evidence demonstrate that neutralizing antibodies against CMV confer significant efficacy, of which gB is a major target. However, one shortcoming of past vaccines that targeted only the gB glycoprotein was a failure to induce high titer neutralizing antibody responses that could prevent infection of epithelial cells; live attenuated and adjuvanted recombinant gB vaccines tested in clinical trials induced titers approximately 20-fold below levels associated with natural immunity. Methods: Using an enveloped virus-like-particle (eVLP) technology in which particles are produced in vitro after expression of MLV Gag protein, we have developed a multivalent vaccine that targets the gB protein as well as the gH protein, part of a pentameric complex associated with epithelial cell entry. The eVLPs can be produced in a variety of mammalian cell types, with current production in a GMP-suitable CHO cell line. Results: Electron microscopy (negative staining and immunogold surface labeling) after tangential flow filtration and anion exchange chromatography has confirmed particle structure after purification and surface antigen localization, with antigen density quantified by ELISA. Immunization of balb/c mice with recombinant gB or the same dose of gB presented in eVLPs demonstrates much stronger (~10X) neutralizing antibody responses induced with the eVLPs, which is associated with a strong Th1 response. Immunization of rabbits with our clinical candidate, comprised of gB and gH eVLPs absorbed to alum, has demonstrated significant neutralizing antibody responses within 2 weeks of the first immunization; titers 2 weeks after the second immunization are greater or comparable to that of natural immunity in fibroblast and epithelial cells, respectively. Conclusions: Combined use of eVLP delivery and CMV antigens in addition to gB represents a potent and safe approach to CMV vaccine development.
Biography
David E. Anderson is a co-founder of VBI Vaccines, a vaccine development company dedicated to innovative formulation, development & delivery of vaccines that expand coverage and enhance protection in both established and emerging markets. He currently serves as Vice President, Research, and is actively involved in management of preclinical research efforts and for building and protecting VBI?s intellectual property. Prior to joining VBI, He served as a consultant to the company while directing academic research as an Assistant Professor at Harvard Medical School. At Harvard, he developed a multi-disciplinary research program focused on elucidating mechanisms by which inflammation is regulated within the central nervous system, with relevance to a variety of human neurodegenerative diseases, including brain tumors, multiple sclerosis, and Alzheimer?s disease. He is a highly published investigator, appearing as primary author on studies appearing in the most prestigious scientific journals, including Nature and Science. He has been invited to give lectures at international conferences in the United States and abroad. He completed his undergraduate studies at the University of California, Davis and received a Ph.D. in Immunology from Harvard University.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version